NEWMarkets
Abbott Labs Upgraded by Rothschild Redburn for Device Strength
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowRothschild Redburn has upgraded Abbott Laboratories' (ABT) stock rating, citing strong performance in its medical device segment. This upgrade reflects confidence in the company's growth potential amid a competitive landscape. The specific rating levels and projections were not disclosed in the article. Such upgrades can positively influence investor sentiment and stock price movement for Abbott Labs, positioning it favorably in a challenging market.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
